Loading organizations...
§ Venture Capital · Mansfield, MA, USA
Corporate venture capital investing in early-stage medical device and health technology startups, focused on strategic alignment.
Covidien Ventures functions as the strategic venture capital arm of Covidien, identifying and investing in early-stage medical technology companies. The firm targets enterprises pioneering innovative medical devices, advanced diagnostics, and novel pharmaceuticals. Its objective is to foster growth in areas aligning with Covidien’s healthcare interests, providing capital and strategic support to accelerate promising solutions.
Established by global medical technology leader Covidien, Covidien Ventures was formed to leverage external innovation. The driving insight was enhancing Covidien's pipeline through targeted investments. This approach supported disruptive technologies poised to significantly improve patient outcomes and expand treatment options within the healthcare sector.
The firm’s primary beneficiaries are the innovative startup companies it funds, gaining crucial financial backing and industry expertise. Covidien Ventures' mission centers on cultivating a robust ecosystem of next-generation medical technologies. By backing promising ventures, the firm aspires to accelerate advanced healthcare solutions, transforming patient care across diverse medical disciplines.
Covidien Ventures has 4 tracked investments across 3 companies. The latest tracked deal is $27.0M Other Equity in SetPoint Medical in August 2013.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 8, 2013 | SetPoint Medical | $27.0M Other Equity | — | Action Potential Venture Capital, Boston Scientific, Foundation Medical Partners, GlaxoSmithKline, Morgenthaler Ventures, Topspin Partners |
| Aug 1, 2013 | SetPoint Medical | $27.0M Series C | — | Action Potential Venture Capital, Morgenthaler Ventures, NEW Enterprise Associates (NEA), Norwest Venture Partners, Runway Growth Capital, ShangBay Capital, Boston Scientific, Foundation Medical Partners, GlaxoSmithKline, Topspin Partners |
| Mar 1, 2013 | Nevro | $48.0M Series C | Novo Ventures | Canaan Partners, Johnson & Johnson Innovation, Pivotal BioVenture Partners, Accuitive Medical Ventures, BAY City Capital, Jlabs, Mayo Clinic, MPM Capital, NEW Enterprise Associates, Three Arch Partners |
| Aug 17, 2011 | Entellus Medical | $35.0M Other Equity | Covidien Ventures | Greenspring Associates, Split Rock Partners, SV Health Investors |